Physician profile
Niranian Dass
NPI 1255650776
$448.34
in general payments reported to CMS, 2019-2025
10 companies · $232 in 2025
The $232 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.09 · 2021: $31.68 · 2022: $57.05 · 2023: $18.82 · 2024: $63.40 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $118.80 | 2021-2025 | Immunocap |
| Cranial Technologies, INC | $70.86 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $58.37 | 2019-2025 | Gardasil 9, Rotateq, Enflonsia |
| Kowa Pharmaceuticals America, INC. | $48.32 | 2025 | Zoryve |
| Sanofi Pasteur INC. | $40.50 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $28.54 | 2025 | Neffy |
| Seqirus USA INC | $23.75 | 2025 | Flucelvax |
| Glaxosmithkline, LLC. | $22.66 | 2025 | Pediarix, Rotarix, Bexsero |
| Pfizer INC. | $22.42 | 2024 | |
| Biomerieux INC | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranian Dass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.